Literature DB >> 15466889

Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line.

Alicia Llorente1, María C de Marco, Miguel A Alonso.   

Abstract

MAL, BENE and MAL2 are raft-associated integral membrane proteins of the MAL family of proteins involved in membrane trafficking processes. We show here that the human prostate carcinoma PC-3 cell line expresses the transcripts for the three proteins simultaneously. MAL, BENE and MAL2 co-fractionated with caveolin-1 in the raft fraction of PC-3 cells, and immunofluorescence analysis showed colocalization of these proteins with caveolin-1 in a multivesicular intracellular compartment. Markers of the Golgi apparatus, early and recycling endosomes and lipid droplets were excluded from this compartment. Prostate epithelial cells contain vesicular organelles enriched in raft components named prostasomes that are secreted in the prostate fluid. Interestingly, the prostasome fraction isolated from the culture supernatant of PC-3 cells consisted mainly of 30-130 nm cup-shaped vesicles that were positive for MAL, caveolin-1 and CD59, a glycosylphosphatidylinositol-anchored protein previously found in prostasomes. CD63, an integral membrane protein found in multivesicular bodies/lysosomes and secretory granules was also found in PC-3 cell-derived prostasomes. Prostasome secretion was not inhibited by brefeldin A, a compound that blocks the conventional secretory pathway. However, wortmannin, an inhibitor of phosphatidylinositol-3 kinase, reduced the secretion of prostasomes in PC-3 cells. Our results suggest that MAL family proteins are associated with caveolin-1 in a multivesicular compartment that may be involved in prostasomal secretion in PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466889     DOI: 10.1242/jcs.01420

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  43 in total

1.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

2.  MAL, but not MAL2, expression promotes the formation of cholesterol-dependent membrane domains that recruit apical proteins.

Authors:  Sai P Ramnarayanan; Pamela L Tuma
Journal:  Biochem J       Date:  2011-11-01       Impact factor: 3.857

Review 3.  Emission of membrane vesicles: roles in complement resistance, immunity and cancer.

Authors:  David Pilzer; Olivier Gasser; Oren Moskovich; Jurg A Schifferli; Zvi Fishelson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

4.  CMTM3 presents a secreted form released via exosomes.

Authors:  Baocai Liu; Henan Li; Weiwei Fu; Yingying Cheng; Wanqiong Yuan; Wanchang Liu; Hui Xue; Xiaoning Mo
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-28       Impact factor: 3.848

5.  PIKfyve inhibition increases exosome release and induces secretory autophagy.

Authors:  Nina Pettersen Hessvik; Anders Øverbye; Andreas Brech; Maria Lyngaas Torgersen; Ida Seim Jakobsen; Kirsten Sandvig; Alicia Llorente
Journal:  Cell Mol Life Sci       Date:  2016-07-20       Impact factor: 9.261

6.  Expression of PTRF in PC-3 Cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways.

Authors:  Kerry L Inder; Yu Zi Zheng; Melissa J Davis; Hyeongsun Moon; Dorothy Loo; Hien Nguyen; Judith A Clements; Robert G Parton; Leonard J Foster; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2011-10-26       Impact factor: 5.911

7.  Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.

Authors:  Kirsten Sandvig; Alicia Llorente
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

8.  Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.

Authors:  Gholamreza Tavoosidana; Gunnar Ronquist; Spyros Darmanis; Junhong Yan; Lena Carlsson; Di Wu; Tim Conze; Pia Ek; Axel Semjonow; Elke Eltze; Anders Larsson; Ulf D Landegren; Masood Kamali-Moghaddam
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

9.  Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

Authors:  Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones
Journal:  Biomark Insights       Date:  2007-12-11

Review 10.  The role of caveolin-1 in prostate cancer: clinical implications.

Authors:  T C Thompson; S A Tahir; L Li; M Watanabe; K Naruishi; G Yang; D Kadmon; C J Logothetis; P Troncoso; C Ren; A Goltsov; S Park
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-07-07       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.